Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04908852 · ClinicalTrials.gov registry record
Feasibility Pilot Exploring Variability in Biomarkers and PROs in AML
A clinical trial, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- 10
- Enrollment target
NCT04908852: Completed study, sponsored by Dana-Farber Cancer Institute.
NCT04908852 is a clinical trial that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04908852 has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- 10 participants
- Enrollment target
Study Summary
This research study is being conducted to help understand how the symptoms during treatment for acute myeloid leukemia (AML) may be affected by metabolism and how best to study this association. Symptoms include experiences like fatigue, sleep disturbance, pain, and depression.
Primary Outcome
Evaluate the feasibility of conducting this type of study on an in-patient oncology unit (i.e., \>70% of enrolled participants will complete 30-day outcome assessments). Using descriptive statistics, feasibility will be calculated as the percent of eligible participants who enroll in the study and among those who enroll, the percent who complete the study. Using a 90%-exact binomial confidence interval estimate, 8 out of 10 participants completing the 30-day study will be considered acceptable f
Interventions
- OTHER Blood Sample Collection - Observational Study
- OTHER Symptom questionnaires - Observational Study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2021-07-26 |
| Est. Completion | 2023-02-23 |
What the finished NCT04908852 record still lists
NCT04908852 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 10 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Blood Sample Collection - Observational Study is the first listed.
NCT04908852 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04908852 about?
NCT04908852 is a clinical study titled "Feasibility Pilot Exploring Variability in Biomarkers and PROs in AML". This research study is being conducted to help understand how the symptoms during treatment for acute myeloid leukemia (AML) may be affected by metabolism and how best to study this association. Symptoms include experiences like fatigue, sleep disturbance, pain, and depression.
What is the current status of trial NCT04908852?
This trial is currently completed. The enrollment target is 10 participants. The study started on 2021-07-26. Estimated completion is 2023-02-23.
What interventions are being tested in trial NCT04908852?
The interventions under investigation include: Blood Sample Collection - Observational Study (OTHER), Symptom questionnaires - Observational Study (OTHER).
Who is sponsoring clinical trial NCT04908852?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI